Baker McKenzie Advises Current Shareholders (Including Funds Advised by ARCHIMED as Controlling Shareholder) on the Sale of Citieffe Group to PolyMed | Newsroom

Baker McKenzie advised the current shareholders on the sale of all their equity interests in Medistream SA, a Swiss corporation holding all equity interests in Citieffe SRL, an Italian medical devices manufacturer, and its subsidiaries in the United States and Mexico (“Citieffe Group”), to Poly Medicure B.V., Amsterdam, Netherlands, a wholly owned subsidiary of Poly Medicure Limited, an Indian public company (“PolyMed”). Funds advised by ARCHIMED, a global private equity firm focused on the healthcare sector, were the majority shareholders in Citieffe Group.

The Citieffe Group is an Italy-based manufacturer specializing in the orthopedic trauma and extremities segment, with a direct presence in Italy, the United States and Mexico, as well as distribution across 25 countries. The transaction was completed on 6 November 2025.

This strategic acquisition provides PolyMed with a gateway into the global orthopedics market, particularly in the trauma and extremities segment — the fastest growing and most resilient category within orthopedics. As part of PolyMed, the Citieffe Group is expected to benefit from enhanced R&D and manufacturing capabilities, including potential cost efficiencies through operations in India.

Baker McKenzie advised the shareholders of Citieffe Group, including ARCHIMED, on all legal and tax aspects of the transaction.

M&A Partners Alexander Fischer and Olha Deminaniuk led the team, which included Alexander Blaeser (partner, M&A), Susanne Liebel-Kotz (partner, tax), Vinzenz Sutter (associate, M&A), Kiara Sharifi (associate, M&A), Kasper Projer (associate, Dispute Resolution/International Commercial & Trade) and Anna Zellweger (associate, International Commercial & Trade).